UK lung cancer study demonstrates further evidence on importance of CT screening
Currently the third most common cancer in the UK, lung cancer affects 40,000 people annually
Read More
Tag: emphysema
Draft NICE decision rejects Respreeza for incurable, genetic disorder
NICE has published draft guidelines rejecting NHS use of CSL Behring’s Respreeza for treating emphysema in adults with severe alpha-1-proteinase inhibitor deficiency.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
